Three Motley Fool contributors think they've found unstoppable dividend stocks to buy right now. Here's why they picked ...

Daily stock price moves often dominate headlines, but shifts in fundamental ranking scores can reveal a deeper story. This ...

Alphabet, Exxon Mobil, and AbbVie remain Zacks' top coverage picks as each navigates industry shifts while driving long-term ...

NORTH CHICAGO, IL, USA I August 21, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 ...

Thursday, August 21, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet ...

A new campaign from AbbVie highlights the “full selves” of people with conditions treated by the company’s therapies, in a ...

For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for the hair-loss disease alopecia areata (AA). | For the second time ...

AbbVie on Thursday said the Phase 3 study evaluating the safety and efficacy of Rinvoq in patients with severe forms of the disease that causes sudden hair loss met its primary endpoint of 80% or more ...

AbbVie Inc. has turned heads recently with a notable uptick in stock searches. Over the last month, its shares soared by +9.2 ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

AbbVie Inc. is in the spotlight as Cantor Fitzgerald revises its FY2025 EPS forecast upwards. Analysts now anticipate $12.05 ...

In ancient Celtic folklore, Tír na nÓg is the land of eternal youth, where time stands still and people don’t age. Today, in the west of Ireland, they’ve come close to bottling it. Westport, a small ...